These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. Lebastchi J; Ajluni N; Neidert A; Oral EA J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101 [TBL] [Abstract][Full Text] [Related]
3. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy. Akinci G; Akinci B Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498 [TBL] [Abstract][Full Text] [Related]
4. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174 [TBL] [Abstract][Full Text] [Related]
5. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105 [TBL] [Abstract][Full Text] [Related]
7. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. Diker-Cohen T; Cochran E; Gorden P; Brown RJ J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254 [TBL] [Abstract][Full Text] [Related]
9. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. Esfandiari NH; Rubenfire M; Neidert AH; Hench R; Eldin AJ; Meral R; Oral EA Clin Diabetes Endocrinol; 2019; 5():4. PubMed ID: 30923630 [TBL] [Abstract][Full Text] [Related]
11. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy. Miehle K; Stumvoll M; Fasshauer M; Hierl T Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984 [TBL] [Abstract][Full Text] [Related]
12. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis. Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100 [TBL] [Abstract][Full Text] [Related]
13. Update on Therapeutic Options in Lipodystrophy. Akinci B; Meral R; Oral EA Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487 [TBL] [Abstract][Full Text] [Related]
14. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy. Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866 [TBL] [Abstract][Full Text] [Related]
15. Effects of Metreleptin in Pediatric Patients With Lipodystrophy. Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110 [TBL] [Abstract][Full Text] [Related]
16. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115 [TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599 [TBL] [Abstract][Full Text] [Related]
18. Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report. Pedicelli S; de Palma L; Pelosini C; Cappa M Ital J Pediatr; 2020 Oct; 46(1):158. PubMed ID: 33099310 [TBL] [Abstract][Full Text] [Related]